BioCentury | Mar 24, 2018
Product Development

Optimism for A2A

...BCIQ: BioCentury Online Intelligence Company Compound Phase Indication Palobiofarma S.L. / Novartis AG (NYSE:NVS; SIX:NOVN) PBF-509...
BioCentury | Mar 31, 2016
Distillery Therapeutics

Therapeutics: Adenosine A1 receptor (ADORA1)

...and safety of the nanoparticle conjugate in various models of respiratory complications. Palobiofarma S.L. has PBF-680...
BioCentury | Oct 26, 2015
Company News

Palobiofarma, Novartis deal

...Palobiofarma granted Novartis exclusive, worldwide rights to develop and commercialize PBF-509 . Palobiofarma said the adenosine...
BioCentury | Oct 22, 2015
Company News

Novartis strikes cancer deals with Admune, Palobiofarma

...LLC (Danvers, Mass.) and obtained exclusive, worldwide rights to non-small cell lung cancer (NSCLC) candidate PBF-509...
...to disclose financial terms of the deal (see BioCentury, May 4, 2015) . Palobiofarma said PBF-509...
BioCentury | Aug 17, 2015
Product Development

Structure knows best

...According to ClinicalTrials.gov, Palobiofarma S.L. in July started a Phase I trial of A2A antagonist PBF-509...
Items per page:
1 - 5 of 5